The San Raffaele ALS Centre

Ospedale San Raffaele

The San Raffaele ALS Centre is dedicated to providing the highest level of care for people and families with ALS.

Ospedale San Raffaele
Ospedale San Raffaele

Our multidisciplinary team of experts is committed to providing the highest level of diagnostic accuracy and patient care. This is done using the latest neurophysiological tests, MRI scans, nerve and muscle techniques. Our scientific interests range from basic research, such as novel drug development or studies using disease models of ALS, to clinical studies (e.g clinical trials, MRI studies). We are part of the Institute of Experimental Neurology (INSPE), which is dedicated to translational research in the neuroscience field, and we collaborate with several laboratories in Italy and Europe.

Contact
Location
Ospedale San Raffaele, Via Olgettina Milano, Milan, Metropolitan City of Milan, Italy
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more